CTOs on the Move

GFI LAB

www.gfilab.com

 
GFI LAB is a Rockwood, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.gfilab.com
  • 681 Main St
    Rockwood, PA USA 15557
  • Phone: 877.236.2522

Executives

Name Title Contact Details

Similar Companies

Predictive Biosciences

Predictive Biosciences is an innovative developer of molecular diagnostic tests for cancer diagnosis and monitoring. We are focused on understanding and meeting the needs of physicians by providing valuable diagnostic services and laboratory solutions.

Biochrom

Biochrom is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABclonal

Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes.

Priovant Therapeutics

Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.

BioMarin

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. The efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. Our track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in our culture. The company`s product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates.